Niagen Bioscience Inc. reports strong Q2 2025 performance with 37% revenue growth and increased full-year financial outlook, positioning the company for sustained growth in the life sciences sector.

Niagen Bioscience Inc has expanded its flagship product, Niagen IV, to nearly 600 clinics nationwide, positioning the company for growth and increased market share in the healthy aging solutions sector.

Niagen Bioscience Inc. has expanded the availability of its Niagen IV therapy, a pharmaceutical-grade NAD+ treatment, to nearly 600 clinics across the US, marking a significant increase in its clinical footprint.

Niagen Bioscience Inc has appointed Dr. Pinchas Cohen to its Scientific Advisory Board, a move that could redefine the company’s trajectory and drive innovation in the life sciences tools and services industry.